Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Stage/Subtype:  recurrent non-small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 194 for your search:
Start Over
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BPI-2358-103, NCI-2015-01970, NCT02504489
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8273-CL-0302, NCI-2016-00113, 2015-002894-39, NCT02588261
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: X396-CLI-301, NCI-2016-00877, NCT02767804
Lung-MAP: Nivolumab with or without Ipilimumab as Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400I, NCI-2016-00050, NCT02154490, NCT02785952
A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-817, NCI-2016-01551, 2016-002621-10, NCT02869789
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients with Stage II-IIIB Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1058, NCI-2012-01224, NCT01629498
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00006, NCI-2013-02416, 2015-003715-38, NCT02000947
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Ibrutinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer with an EGFR Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0602, NCI-2015-00124, NCT02321540
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, NCT02327078
Start Over